AAAnastasia A. Andrianova

Anastasia A. Andrianova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anastasia A. Andrianova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Chemical Tuning of Fungal Bioluminescence in Mammalian Systems

    by Anastasia A. Fadeeva, Aleksei D. Barykin, Andrey Bubyrev, Nadezhda M. Markina, Tatiana V. Chepurnykh, Anastasia A. Andrianova, Ekaterina S. Shakhova, Maxim A. Abakumov, Anastasiia S. Garanina, Renata I. Zagitova, et al.

    Fungal bioluminescence is a genetically encodable platform with potential for bioimaging in mammalian systems but remains limited by low signal intensity. Here, we report a series of fungal luciferin analogs designed by modification of the arylidene fragment. Electron‐donating substituents generally increase activity, whereas extension of π ‐conjugation red‐shifts emission, with partial decoupling of these effects. These trends parallel those observed for firefly luciferins, indicating that empirical design principles can be transferred between the two systems. Evaluation across fungal luciferases and engineered variant v4, demonstrated broad substrate compatibility and highlighted the combined potential of luciferase engineering and luciferin modification for improving fungal bioluminescence in mammalian bioimaging.

  • Beyond Antiviral Therapy: Untapped Potential of HIV & HCV Protease Inhibitors

    by Dmitrii A. Iuzabchuk, Anastasia A. Andrianova, Ilia V. Yampolsky, Zinaida M. Kaskova, Ivan V. Smirnov

    Development of de novo therapeutic agents is a complex, costly, and a high‐risk process, whereas repurposing approved and investigational drugs for novel targets offers a more efficient and cost‐effective strategy, likely yielding higher success rates. This approach demonstrated its effectiveness during SARS‐CoV‐2 pandemic, when existing drugs were repurposed to combat the virus. Originally pivotal in developing antiviral treatments against HIV and HCV, viral protease inhibitors represent a structurally privileged class of compounds capable of targeting difficult and non‐classical protein sites. They have demonstrated promising biological activity against diverse alternative targets, including fungal pathogens, multidrug‐resistant bacteria, and cancer, making them prime candidates for repurposing. This mini‐review highlights the unique structural and physicochemical properties of approved HCV and HIV viral protease inhibitors that enable their repurposing for the development of new therapeutic agents.